Company Strategy & Market Position - Maravai aims to be the customer's first choice by owning the front end of the funnel and winning in discovery[13] - The company's solutions are well-positioned to capture attractive opportunities in the growing mRNA, cell, and gene therapy pipeline, which is expected to grow 4x from 2022 to 2027[15] - Maravai leverages its manufacturing scale, invests in innovation, scales its commercial organization, and pursues inorganic growth opportunities[41] Financial Highlights & Cost Management - As of September 30, 2023, Maravai has $580 million in cash and $534 million in long-term gross debt, resulting in a net debt of -$45 million[43] - The company is targeting at least $30 million in annualized cost savings in 2024[43] - Adjusted Free Cash Flow was $5 million YTD through Q3 2023[44] Nucleic Acid Production (NAP) Segment - Nucleic Acid Production accounted for 77% of the company's business[28] - One customer's sales grew 12x in 4 years, from $619K in 2018 to $7.75M in 2022[32] Biologics Safety Testing Segment - Biologics Safety Testing accounts for 23% of the company's business[35] - Cygnus Technologies' HCP kits are used in all 17 commercialized CAR-T cell and gene therapies plus the first-ever CAR-T approval in China[36]